Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect - Archive ouverte HAL Access content directly
Journal Articles British Journal of Dermatology Year : 2019

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect

, , , , , , , , , , , , , , , , , , , (1, 2) , , , , , , , , , , , , , , , , , , , , , ,
1
2
D M Chen
  • Function : Author
A Odueyungbo
  • Function : Author
E Csinady
  • Function : Author
L Gearhart
  • Function : Author
P Lehane
  • Function : Author
M Cheu
  • Function : Author
M Maho‐vaillant
  • Function : Author
C Prost‐squarcioni
  • Function : Author
V Hebert
  • Function : Author
E Houivet
  • Function : Author
S Calbo
  • Function : Author
F Caillot
  • Function : Author
M L Golinski
  • Function : Author
B Labeille
  • Function : Author
C Picard‐dahan
  • Function : Author
C Paul
  • Function : Author
M A Richard
  • Function : Author
J D Bouaziz
  • Function : Author
S Duvert‐lehembre
  • Function : Author
F Caux
  • Function : Author
M Alexandre
  • Function : Author
S Ingen‐housz‐oro
  • Function : Author
P Vabres
  • Function : Author
E Delaporte
  • Function : Author
G Quereux
  • Function : Author
A Dupuy
  • Function : Author
S Debarbieux
  • Function : Author
M Avenel‐audran
  • Function : Author
M d'Incan
  • Function : Author
C Bedane
  • Function : Author
N Bénéton
  • Function : Author
D Jullien
  • Function : Author
N Dupin
  • Function : Author
L Misery
L Machet
  • Function : Author
M Beylot‐barry
  • Function : Author
O Dereure
  • Function : Author
B Sassolas
  • Function : Author
J Benichou
  • Function : Author
P Musette
  • Function : Author
P Joly
  • Function : Author

Abstract

Background Corticosteroids (CS) with or without adjuvant immunosuppressant agents are standard treatment for pemphigus vulgaris (PV). The efficacy of adjuvant therapies in minimizing steroid-related adverse events (AEs) is unproven. Objectives To utilize data collected in a French investigator-initiated, phase III, open-label, randomized controlled trial to demonstrate the efficacy and safety of rituximab and seek approval for its use in PV.
Fichier principal
Vignette du fichier
BJD-182-1111.pdf (2.87 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03434482 , version 1 (18-11-2021)

Licence

Attribution - NonCommercial - NoDerivatives - CC BY 4.0

Identifiers

Cite

D M Chen, A Odueyungbo, E Csinady, L Gearhart, P Lehane, et al.. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect. British Journal of Dermatology, 2019, 182, pp.1111 - 1119. ⟨10.1111/bjd.18482⟩. ⟨hal-03434482⟩

Collections

URCA IRMAIC
16 View
35 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More